Zanubrutinib (Brukinsa®) for marginal zone lymphoma. HTA ID: 23072

Assessment Status Pre submission consultation scheduled
HTA ID 23072
Drug Zanubrutinib
Brand Brukinsa®
Indication Zanubrutinib monotherapy is indicated for adult patients with relapsed/refractory marginal zone lymphoma with at least one prior anti-CD20-based therapy.
Assessment Process
Rapid review commissioned 01/12/2023
Rapid review completed 09/01/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of zanubrutinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/01/2024